ScripNew data from Aptose Biosciences’ Phase I/II TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) show patients receiving 40mg or 80mg of the once-daily, oral multi-kinase inhibitor tuspetini
ScripDozens of public biopharmaceutical companies have announced plans in 2025 to assess strategic alternatives after clinical trial setbacks or as cash stockpiles dwindled. Both ESSA Pharma and Elevation
ScripA series of confirmed complete remissions at various doses in patients receiving Hanmi Pharmaceutical Co., Ltd. ’s in-house-developed innovative drug for acute myeloid leukemia (AML), HM43239, are mo
ScripAs more South Korean pharma companies seek to globalize and do cross-border license deals, licensing-related income and sales from overseas subsidiaries appear to be taking on greater weight in their